cor2ed
engage checkpoint medical linkedin twitter
bg

HCC treatment algorithm with systemic therapy based on the recently updated HCC guidelines

HCC treatment algorithm with systemic therapy based on the recently updated HCC guidelines

Assoc. Prof. Aiwu Ruth He, Assoc. Prof. Matthias Pinter

Professor He and Professor Pinter, discuss their perspectives and experience on how to select systemic therapy options in first line and beyond for patients with advanced or unresectable HCC based on the current international HCC guidelines.
Portrait of Aiwu Ruth He
Assoc. Prof. Aiwu Ruth He

Medical Oncologist

Georgetown University School of Medicine

United States (US)

Portrait of Matthias Pinter
Assoc. Prof. Matthias Pinter

Hepatologist

Medical University of Vienna

Austria

preview next

time Expert View | open 30 min

I agree that this educational programme:

Was valuable to me:

1/3

Insights from Professor He and Professor Pinter on the international HCC guidelines including NCCN, ASCO, ESMO, ILCA, AASLD and EASL which were revised in late 2020 and in 2021 to include atezolizumab+bevacizumab immunotherapy combination as the new standard of care in first line setting for patients with advanced or unresectable HCC. They discuss which guidelines they follow in their clinical practice and mainly how to select the first systemic therapy option for patients with advanced or unresectable HCC. An Infographic is also available proposing an algorithm providing the criteria to select between lenvatinib and sorafenib in 1L for patients not eligible for atezolizumab+bevacizumab and propose the treatment option sequencing for 2L and beyond after atezolizumab+bevacizumab for patients with advanced or unresectable HCC.

 

Other programmes of interest

Other programmes developed by Assoc. Prof. Aiwu Ruth He